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Clinical trials are the standard approach for evaluating new treatments, but
may lack the power to assess rare outcomes. Trial results are also necessarily
restricted to the population considered in the study. The availability of routinely
collected healthcare data provides a source of information on the performance
of treatments beyond that offered by clinical trials, but the analysis of this type of
data presents a number of challenges. Hierarchical methods, which take advan-
tage of known relationships between clinical outcomes, while accounting for
bias,may be a suitable statistical approach for the analysis of this data. A study of
direct oral anticoagulants in Scotland is discussed and used to motivate a mod-
eling approach. A Bayesian hierarchical model, which allows a stratification of
the population into clusters with similar characteristics, is proposed and applied
to the direct oral anticoagulant study data. A simulation study is used to assess
its performance in terms of outcome detection and error rates.
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1 INTRODUCTION
Clinical trials remain the standard method for establishing the efficacy and safety of new treatments.1 While clinical tri-
als are able to provide a causal analysis of the relationship between treatments and outcomes, they also have a number
of potential limitations. If the trial population does not reflect the general population on which the treatment is actually
used once approved there may be some concern about the generalizability of the trial results;2 a trial may only compare
a small number of possible treatments for any particular condition, even if many such treatments are available; further-
more, as the trial is generally sized to answer a primary objective, the power to detect differences for any additional
hypotheses, including the detection of safety issues,may be reduced. For approved treatments, postmarketing surveillance
provides longer term safety analysis outside of the trial environment. A number of regulatory agencies and drug monitor-
ing centers have developed computerized methods for identifying potential serious adverse outcomes using spontaneous
report adverse event databases.3 For example, the US Food and Drug Administration (FDA) use a Bayesian data-mining
approach4 and the World Health Organization (WHO) use a Bayesian neural network.5
Assessing the generalizability of treatments to populations not covered by clinical trials, or indeed assessing new
treatments in comparison with preexisting treatments, may be difficult, if not impossible, based on clinical trial
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results alone, and will require the use of nontrial data beyond that provided by adverse event reporting databases.
These types of analyses may be considered part of a comparative effectiveness research (CER) approach which seeks
to compare healthcare interventions to determine which work best in the sense that they provide the most bene-
fits and the least harm to patients, bringing the prospect of a precision medicine approach for individual patients
closer.
Sources of information beyond trial data and adverse event reporting databases are becoming increas-
ingly available to healthcare researchers. In particular many national healthcare providers record information
about patient demographics, issued prescriptions, treatment duration, adherence, co-morbidities, hospitalizations,
and other outcomes of different treatment regimes. These records together with national registers of births
and deaths provide a source of information regarding the relative performance of different treatments in the
general population. This data are constantly accumulating as new patients interact with the relevant health
bodies.
The analysis of this type of observational data provides a number of logistical and statistical challenges. Data may
come from multiple sources with conflicting or contradicting information and may require significant clean-up before it
can be analyzed. Patient outcomes, either recorded as ICD-101 codes or locally coded, may not map directly to adverse
event definitions as defined by clinical trials, making comparisons with trial outcomes difficult. So while we may expect
to see similar patterns of outcomes for patients under treatment in the general population as we have seen in clin-
ical trials, the lack of a direct general mapping between the two sets of outcomes will make this more difficult to
determine.
The structure and balance provided by clinical trials does not exist in observational data and the analysis of the data
may be inhibited by bias, for example, by treatment indicator. The use of methods such as propensity score analysis or
inverse probability of treatment weighting (IPTW), under certain assumptions, is possible approaches to handling bias,
but there is no objectivemethod for defining a causal analysis in an observational study.6 More recent developments using
genetic indicators or similar instrumental variables have the potential to provide a “quasi-randomization” of the observed
populations, opening the possibility of more balanced treatment comparisons.7
In observational studies, outcomes are often modeled individually. This has a number of statistical implica-
tions. Modeling individually excludes the possibility of using relationships, which may exist between the out-
comes in the analysis, and there is no straightforward way of assessing the impacts of the outcomes together in
order to make a decision about which treatments are suitable for particular patients. There is also the poten-
tial lack of control for multiple comparisons, leading to the possibility of spurious associations being detected in
the data.
In clinical trials patient outcomes, such as adverse events, may be defined by specific clinical symptoms or labora-
tory measurements, and may be the clinical expression of the effect a drug has on a particular organ or body-system.
For example, in the United States National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
(CTCAE),2 adverse events such as cholecystitis and hepatic pain are defined as part of the hepatobiliar disorders grouping
of events and would typically be reported separately. Most medical dictionaries, for example, MedDRA or WHO-ART,
define a hierarchical structure consisting of system organ classes (SOCs), various groupings (higher level terms), and
descriptor or preferred terms for describing the adverse event itself. In clinical trial, study reports safety data are often
presented grouped by system organ class andmethods, which take advantage of this type of grouping approach have been
developed for adverse event analysis.8-10 These methods assume that in a SOC affected by a treatment we may be more
likely to see raised occurrence rates for a number of related adverse events within that SOC and the analysis tries to take
advantage of this extra information when modeling the data. While ICD-10 codes do provide a hierarchy of sorts for non-
trial patient data, the groupings of outcomes is not as well defined as those supplied in medical dictionaries and generally
used in trials.
In Section 2, an existing study of direct oral anticoagulants is introduced and a number of the characteristics that affect
the analysis of this type of data are discussed and used to motivate a Bayesian hierarchical modeling approach based on
the adaption of existing clinical trial methods. In Section 3, we extend the some of these clinical trial approaches to allow
multiple treatments and outcomes, with patients grouped into stratified clusters, for use in an observational setting. The
methods are applied to a simulated study to assess their performance and error rates (Section 4.1) and then to data from
the study of direct oral anticoagulants in Scotland (Section 4.2).
1International Classification of Disease codes, 10th edition.
2CTCAE Version 4.0: http://evs.nci.gov/
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TABLE 1 DOAC prescription characteristics for the Forth Valley health board
Health board Treatment
First recorded prescription
(days since drug approval)a
Last recorded prescription
(days to end of study)b
Forth Valley Dabigatran 10/11/2011 (97) 31/08/2014 (497)
Forth Valley Apixaban 07/08/2013 (208) 18/12/2015 (13)
Forth Valley Rivaroxaban 02/05/2012 (110) 30/12/2015 (1)
aFor example, the 10/11/2011 was the date of the first recorded Dabigatran prescription in the Forth Valley health board, and this
was 97 days after the drug was approved for use.
bFor example, the 31/08/2014 was the date of the last recorded Dabigatran prescription in the Forth Valley health board, and this
was 487 days before the end of the study date.
2 CASE STUDY: DIRECT ORAL ANTICOAGULANT SCOTLAND STUDY
(2011-2015)
The DOAC Scotland Study (2011-2015) is a study of the comparative safety and effectiveness of direct oral anticoagulants
(DOACs) in Scotland for patients with a hospital confirmed diagnosis of atrial fibrillation, fromAugust 2011 to December
2015.2 The study population consisted of 14788 patients initiating one of three treatments: Apixaban, Dabigatran, or
Rivaroxaban. The data were analyzed using a number of different approaches, including Cox regression on the index
treatment (the first treatment received), with censoring on patient death, treatment discontinuation, or treatment switch.
A number of different outcomes as identified by ICD-10 codes were analyzed. The main conclusions of the original study
were that the risk of Myocardial infarction was higher among Apixaban patients in comparison with Dabigatran and
Rivaroxaban, thatRivaroxabanpatients also had ahigher risk ofPulmonary embolism thanApixabanpatients, and that the
risk of Other bleed and Gastrointestinal bleed was higher among Rivaroxaban patients than for Apixaban and Dabigatran
patients.
A causal analysis of this data is frustrated by a number of factors beyond the control of the investigator. For the study
period Scotland was covered by 14 health boards each with their own prescribing rules. Economic and other factors
may see health boards select particular DOACs as the drug of choice for patients,3 limiting or eliminating the exposure
of patients to the other DOACs. As an example in the Forth Valley health board there were 487 days between the last
recorded prescription for Dabigatran and the end of the study (Table 1). Indeed over the course of the study, there was
no single continuous time period where all three treatments appeared to be available to all patients, although for each
individual health board, there were there were periods of overlap. A further analysis of this type of study would typically
involve propensity scoring or IPTW11 and an IPTW analysis restricted to patients who initiated treatment during these
overlapping periods was in agreement with the original study conclusions and provided no evidence for confounding by
treatment indication.
In order to further the analysis we consider what additional information exists in data that we can make use of in a
different modeling approach. While time to first adverse outcome or event is an important safety measure, any following
outcomes also provide information on treatment safety. Not including these recurrent outcomes may reduce the power
to detect differences between treatments. Similarly censoring at treatment switching, or discontinuation followed by a
treatment restart, also removes recurrent outcomes from the analysis for that patient. For treatments like DOACs, where
the drug half-life may be less than a day,12 a patient initiating a different treatment after a discontinuation could in effect
be considered to have started afresh and this data should be included in an analysis. Patients may have many different
outcomes over the duration of their treatment. Assessing the relative risks of these outcomes when deciding a treatment
regime for a patient requires some sort of combined analysis, which is not readily available from single event outcome
models such as Cox regression. The ability to take advantage of relationships that may exist between different outcomes
in an analysis should allow for more precise effect estimation and hence reliable decisionmaking. Lack of balance within
observational datamay be catered for by dividing the population into clusters with similar characteristics, allowingwithin
cluster inferences to be made.
Hierarchical Bayesian models for multiple outcome modeling have been proposed both for clinical trial data and
for data mining observational data.9,10,13-16 These approaches offer the possibility of both borrowing strength between
3http://www.ggcmedicines.org.uk/blog/edoxaban-doac-choice-non-valvular-atrial-fibrillat/
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the different effects and shrinking nonsignificant effects toward zero, while controlling for multiple comparisons.17 In
the next section, we look to extend some of these clinical trial approaches to allow multiple treatments, with patients
grouped into stratified clusters, for use in an observational setting. The use of identified clusters rather than covariates to
stratify data has a number of advantages. It reduces the number of variables in the model, particularly when the model is
hierarchical, and it allows the use of any number of stratifying approaches, including geneticmarkers if they exist, without
any changes to the model structure. Clusters or groups of patients may be identified by matching, as in case-control
studies; however, for rare outcomes where large numbers of clusters would reduce the numbers of outcomes in each
cluster to very low levels, unsupervised approaches may be needed to define a limited number of potentially interesting
clusters. This type of approach may not be as easily achieved with covariate-based models. In these cases, there may be a
level of uncertainty with regard to clustermembership and there is the potential tomodel this uncertainty and to integrate
this into the modeling process. While recent approaches to the analysis of observational data have used regularization
methods to allow the estimation of propensity scores frommodels containing thousands of variables,18 and applied these
methods in large scale studies,19 the model we present here is complementary to the type of targeted univariate analysis
generally used in these approaches. Rather it is designed to analyze multiple related outcomes using defined clusterings
of patients and to determine which clusters of patients are more likely to suffer outcomes, while adjusting for multiple
comparisons. Outcomes identified as possibly associated with particular treatments and clusters are potential candidates
for further targeted analysis.
3 METHODS
An important consideration when adapting trial methods to observational data is the question of incorporating patient
level characteristics into the analysis. In observational data, there is no guarantee of balance between compara-
tor groups and with possibly thousands of patients' data available including individual patient-level parameters and
patient/treatment interactions may lead to a model with thousands of parameters. For a Bayesian analysis using a sam-
pling approach, particularly on systems with limited memory, this may make the model computationally intractable.
However, the inherent bias in patient data requires a level of patient level input. Some existing approaches include patient
level effects in their models but condition or integrate them out, leaving in effect a model containing only treatment
effects.16 Alternatively, stratifying patients into distinct groups, and including this in themodel, is an approach that allows
the inclusion of some level of patient effects. Stratifying the patients into well-balanced clusters should also provide a
level of control for confounding or exploring differences between patient groups. The approach taken here is to include
stratification directly in the model hierarchy if required, where the assumption is that while the outcomes in the dif-
ferent strata may be different, there may be a relationship between the different strata that should be included in the
model.
Themodel proposed in this article is a conditional Poissonmodel based on the approaches in Berry and Berry and Xia
et al,9,13 where the treatment effects are defined as increases in risk relative to a baseline treatment. The related outcomes
aremodeled following a hierarchical structure with each outcome belonging to a particular grouping of related outcomes.
If there are C treatments, H strata, B groupings of outcomes with kb outcomes in group b, then we model the number of
outcomes, X (c)bj,h, for the jth outcome in the bth group for treatment c in stratum h by the following:
X (c)bj,h ∼ Poisson
(
𝜆
(c)
bj,hT
(c)
bj,h
)
T(c)bj,h =
∑
i∈(c)bj,h
tih
log 𝜆(c)bj,h = 𝛾bj,h + x(c)𝜃
(c)
bj,h, (1)
where h = 1,… ,H, b = 1,…B, j = 1,… kb, c = 1,… ,C. x(c) is an indicator variable for the treatment, T(c)bj,h is the total time
spent under treatment c for all subjects in stratum h, 𝜆(c)bj,h is the corresponding underlying rate parameter, 𝛾bj,h is the
log rate of the baseline treatment, and 𝜃(c)bj,h may be considered as the increase or decrease in risk relative to the baseline
treatment.
As this is a Bayesianmodel, the individual parameters have prior distributions. Following Berry andBerry,9 we include
the possibility of no difference between the different treatments through a mixture prior including a point-mass at zero
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which assigns a positive probability to this possibility:
𝛾bj,h ∼ N
(
𝜇𝛾b, 𝜎
2
𝛾b
)
𝜃
(c)
bj,h ∼ 𝜋
(c)
b I[𝜃(c)bj,h=0] +
(
1 − 𝜋(c)b
)
N
(
𝜇
(c)
𝜃b , (𝜎
(c)
𝜃b )
2
)
. (2)
A three-level hierarchy is defined for the remainder of themodel. The fullmodel is given inAppendixA1. The presence
of the point-mass term in the distribution of 𝜃(c)bj,h (2) in effect provides a barrier or hurdle that requires a strong signal
(increase or decrease in rate) in order for 𝜃(c)bj,h to have a high posterior probability of being positive or negative. Removing
the point-mass term (setting 𝜋(c)b = 0 in (2)) tends to result in increases both in detection and error rates when using 𝜃
(c)
bj,h
as a means of flagging outcomes as being associated with a treatment.10,20
The model is an extension of methods proposed for clinical trial data adapted to multiple treatments and stratified
data.10 Individual patient treatment times and outcomes are summed within the different strata, leading to a summary
data model. A possible criticism of the model is the potential impact that a small number of patients experiencing a large
number of outcomes may have on the model. This is a risk in all summary-level models, but patient stratification has the
potential to insulate patients in different clusters from each other while possibly allowing identification of these types
of patients if they have similar characteristics. Individual treatments are considered to be independent of each other,
they do not borrow strength. The inclusion of relationships between the different treatments requires the incorporation
of domain specific knowledge in the model. In the case of the DOAC study in Section 2, this would require knowledge
of the pharmacokinetics of the treatments. A strength of Bayesian hierarchical modeling is that this type of knowledge
can readily be incorporated into the model,15 making the model more specific to particular treatment areas. In a similar
manner prior knowledge of the known or expected physiological effects for a particular treatment may also be included.
The assumption of independence of treatment should allow comparisons with existing study results, with the inclusion
of the point-mass term in the model providing a level of error control. The original model proposed by Berry and Berry9
effectively treats all patients as a single grouping. Including clustering in the model facilitates balanced comparisons for
different groups of patients, thus helping to identify differences between groupings and control for confounding. The bor-
rowing of strength between clusters provides a level of robustness to inferences made about differences between clusters
in the sense that if there are different effects in different strata then they will need to overcome the effect provided by
the modeled relationships. It is also possible to weaken the assumed relationships between clusters by making changes
to the model hierarchy. The derivation of the cluster and outcome groupings is not part of the modeling approach pre-
sented here. Clustering may be dependent on the level of available patient information, and outcome groupings require
knowledge of the behavior of the treatments. A reference implementation of the model is given in the R package bhpm.21
The model is fitted by Markov chain Monte Carlo (MCMC) methods, in this case Gibbs sampling under assumptions of
conditional independence within the model hierarchy.22
We can contrast the approach to the Bayesian self-controlled cases series model (BSCCS), introduced by Shaddox
et al,16 and to the approach of Crooks et al.15 In the BSCCS model, a drug-era is defined as an interval over which the
drugs a patient takes remain constant. In BSCCS, the number of adverse outcomes Yikp for patient i, for outcome p, in
drug-era k is modeled as:
Yikp ∼ Poisson(likp𝜆ikp)
log 𝜆ikp = 𝜙ip + xTikp𝜷p (3)
where 𝜙ip are the subject's baseline risks, xikp indicates drug exposure, and 𝜷p are the log relative risks for each drug with
respect to the outcomes p. In BSCCS, the subject baseline effects are conditioned out of the model and we essentially end
up with a model which contains only the relative risk effects for each drug. As the model has been conditioned fitting is
done using a numericalmaximum a posteriori (MAP) estimation approach rather than by sampling. Crooks et al15 specify
an approach using a combination of Bayesian and classical methods for detecting gastrointestinal adverse outcomes of
different vaccines. The approach is multilayered, using the reporting odds ratio (ROR)23 as the method of determining
safety signals. The ROR is “propagated” through a number of different classical and Bayesian methods. Initially potential
confounders (eg, age/sex/year of event) are identified and a stratified analysis carried out for each combination of vaccine
and adverse event. Identified confounders are then used in a logistic regression for the ROR and the estimated log odds
ratios and standard errors included in a Bayesian hierarchical analysis and reestimated. This approach to confounding,
including the stratified estimates in the Bayesian model, is similar in spirit to the approach above, but the method of
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determining signals is different. Both the methods of Shaddox et al and Crooks et al are designed to be used on reporting
databases, in the case of Shaddox et al on large-scale claims data, and for Crooks et al on spontaneous reporting databases.
While these provide valuable sources of information, one criticism of studies based on this type of data is that they “only
contain an indication of a reporter's suspicion of an association rather than a real association.”15 Further analysis is needed
to in order to determine if these are real signals. National healthcare records, on the other hand, offer the possibility of
a more complete picture of the population under treatment, including accessing patients' prior histories, comorbidities,
concomitantmedications, laboratory, and, increasingly, genetic data. This data offer the opportunity of performingnatural
experiments and investigating the performance of treatments in the population as a whole. It is anticipated that, similar
to clinical trials, a small number of treatments will be compared. Given the problems associated with performing a causal
analysis encountered in Section 2, alternative methods are needed. A novel aspect of the approach here is the application
of multivariate methods to data which has typically been analyzed one outcome at a time, while allowing comparisons
between different groups of patients, with a level of generality that is not specific to one particular treatment area.
4 RESULTS
4.1 Simulation study
The methods are illustrated and evaluated by a synthetic study of 14 000 patients, split into 10 different clusters
(Cluster1-Cluster10) and treated with one of four different drugs (Drug1-Drug4). The purpose of the simulation is to
assess the detection and error rates of the methods with patients being randomly assigned to clusters with probabilities
given in Table B3. There are different numbers of patients and treatment allocations in each cluster and the average time
under treatment for each patient also varies between the clusters. A single treatment, Drug1, is chosen as the baseline and
we are interested in detecting changes in the relative risks between the other treatments and the baseline treatment. Nine
different outcomes (Outcome1-Outcome9) are included in the study, divided into three groups (Table 2). The underlying
baseline outcome rates for the simulation are sampled from a normal distribution with mean rate of 0.001 per unit time,
and SD 0.0001 (simulated negative rates are set to 0.001). All outcomes in group Group2 have increased rates over all the
clusters for treatment Drug2, and Outcome7 and Outcome8 in group Group3 have increased rates for treatment Drug3 in
cluster Cluster9 only. The details are given in Table 3. Thousand simulations in total were run. The full details of the study
are given in Appendix B1. The simulation explicitly caters for the presence of different effects in different clusters. Two
different types of analyses are performed: one with a separate model fitted to each individual cluster, and one where all
clusters are included in a single hierarchy. Models with and without the point-mass (𝜋(c)b = 0 in (2)) are fitted in all cases.
Although the models may be considered exploratory, in order to provide some assessment of their performance with
regard both to the detection of raised outcome rates and the error rates, some flagging mechanism must be used. As the
methods are Bayesian, we use the posterior probability of an increase or decrease in the event rate relative to the baseline
Group Outcome
Group1 Outcome1, Outcome2
Group2 Outcome3, Outcome4, Outcome5
Group3 Outcome6, Outcome7, Outcome8, Outcome9
TABLE 2 Simulation study outcomes
Treatment Outcome % increase in rate Cluster
Drug2 Outcome3 100 All clustersa
Drug2 Outcome4 50 All clustersa
Drug2 Outcome5 1 All clustersa
Drug3 Outcome7 100 Cluster9
Drug3 Outcome8 10 Cluster9
aRate raised for all clusters in the simulation.
TABLE 3 Outcomes with increased rates
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TABLE 4 Results of the simulation study
Method Clustered analysisa Correctb Incorrectc Missedd Raised ratese Baseline comparisonsf
Point-mass Yes 20 183 7 11 817 32 000 270 000
Point-mass No 18 391 67 13 609 32 000 270 000
No point-mass Yes 21 669 6792 10 331 32 000 270 000
No point-mass No 20 965 10 105 11 035 32 000 270 000
aThe value Yes means a single model (1) was fitted to the data. The value No means that individual models (1) were fitted for each cluster.
bThe total number of outcome, treatment, cluster combinations with raised rates compared with the baseline treatment that were correctly
identified by the model as having a raised rate.
cThe total number of outcome, treatment, cluster combinations that were incorrectly identified by the model as having a raised rate
compared with the baseline.
dThe total number of outcome, treatment, cluster combinations with raised rates that were not identified by the model as having a raised rate
compared with the baseline
eThe total number of outcome, treatment cluster combinations with raised rates compared with the baseline in the simulation study. From
Table 3, Outcome3-Outcome5 are each raised in 10 clusters for Drug2, Outcome7, and Outcome8 are raised in one cluster each for Drug3.
This gives 32 combinations in total with raised rates per simulation.
fThe total number of outcome, treatment, cluster combination comparisons with the base line treatment Drug1. There are three comparison
treatments (Drug2-Drug4), each with nine outcomes over 10 clusters, giving 270 comparisons with the baseline treatment per simulation.
treatment (𝜃(c)bj,h) as a method of determining if an outcome is associated with a treatment (relative to the baseline).
9 For
the purposes of this study we declare that an outcome is associated with a treatment if the posterior probability of an
increase/decrease in rate compared with the baseline is greater than 90% for point-mass models and 95% for models
without the point-mass. Previous simulation studies for similarmodels have shown that the 90% cut-off for the point-mass
model allows the detection of outcomes associatedwith treatment, without inflating themisclassification rate (incorrectly
flagging events as associated with treatment), particularly for higher rate adverse events.10 For low treatment and control
differences the effect of the point-mass is felt most strongly, and lowering the threshold below 90% does not lead to a large
increase in the numbers detected. For the non-point-mass models, a threshold of 95% has proven to be similarly suitable
for simulation studies.10 The situation for calibrating model thresholds in real as opposed to simulated data is necessarily
different with thresholds as high as 99% being suggested.15 A more theoretical method suggested by Chen et al24 is to use
a decision theoretic approach to minimize the loss of misclassifying an outcome as the means of determining threshold
values.
The results in terms of detection and error counts are given in Table 4. We can see that in terms of balancing between
numbers of outcomes correctly detected and errorsmade the clustered point-massmodel could be considered to have per-
formed best overall. It correctly identified 20 183 out 32 000 possible combinations (63%) as having raised treatment rates,
andmisclassified only seven outcomes as being associatedwith treatment.While the clustered non-point-massmodel has
correctly identified more outcome combinations, 21 669 or 68%, it has misclassified 6792 outcomes combinations. Com-
paring the clusteredmodels to their nonclustered equivalents, we can see there is both the evidence of borrowing strength
between related outcomes (increase in the numbers correctly detected) and the shrinkage of nonsignificant effects toward
zero (decrease in the misclassifications) in the clustered model.
Care must be taken when generalizing from simulations. Previous results with these types of model indicate that for
very low outcome rates or short study periods, the non-point-mass models may perform better than their point-mass
equivalent in terms of outcome detection.10 In these cases, the point-mass models may detect few outcomes with raised
rates. Here the effect of the point-mass mitigates against detection. However even for shorter durations, the error rate
in terms of incorrectly flagged outcomes remains much higher than for non-point-mass models.10,20 A number of addi-
tional simulation scenarios considered in the supplementary materials illustrate these model features. For simulations
where the difference in rate is small (Section S.5), the point-mass model struggles to identify outcomes with increased
rates. Outcomes with low rate increase are unable to overcome the effect of the point-mass, whereas the non-point-mass
models correctly detect many more of the outcomes with increased rates, with the rate of misclassification of outcomes
as associated with treatment, being comparable with the other simulations. For simulations with large differences in
treatment outcome rates (Section S.4), the situation is very different. The numbers of outcomes with raised rates that
are correctly detected by the clustered point-mass model exceeds that detected by the non-clustered point-mass model
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Outcome description Grouping Grouping description
Ischemic stroke I00-I99 Circulatory system
Hemorrhagic stroke I00-I99 Circulatory system
Systemic embolism I00-I99 Circulatory system
Pulmonary embolism I00-I99 Circulatory system
Myocardial infarction I00-I99 Circulatory system
Transient ischemic attack G00-G99 Nervous system
Gastrointestinal bleed Bleed Bleeds
Other bleed Bleed Bleeds
Other ADR Other ADR Adverse drug reaction
TABLE 5 Outcomes included in the study
and is comparable with the numbers detected by the clustered non-point-mass model, with much better control of the
misclassification rate.
4.2 Direct oral anticoagulant Scotland study (2011-2015)
The clustered point-mass model is applied to the data from the comparative safety and effectiveness study of direct oral
anticoagulants (DOACs) in Scotland.2 The outcomes analyzed are given in Table 5, together with the groupings used for
the Bayesian analysis. The choice of outcomes corresponds to those used in the original study and the same assumptions
were followed with regard to treatment discontinuation and treatment switching. Counts of all the relevant outcomes,
which occurred to any patient while under any treatment over the duration of the study, were included. The outcomes are
aggregates of different ICD-10 codes, which relate to similar medical incidents.2 The choice of outcomes and groupings
highlights a number of issues with aggregating ICD-10 codes and determining groupings when there is no single standard
available. The groupings used here are guided by ICD-10 code groupings, for example, Circulatory system covers I00-I99.
However, the aggregated outcome Other bleed, used in the original study, also contains the ICD-10 code I62, so we could
plausibly include some of the outcomes in the Circulatory system grouping rather than the Bleeds grouping as we have
chosen.
Due to the relatively small numbers of outcomes, the number of patient stratifications are limited. Two analyses were
performed. One where patients are grouped in a single cluster and one where patients were stratified into a small number
of clusters based on age category in years (0-64, 65+), sex (Male/Female), and number of concomitant medications (0-4,
5+), giving eight clusters in total (Table 6). Cluster size is a problem regardless of the type of analysis performed. While
age and sex are often included in analyses as a priori confounders,15 concomitant medicines may be considered a proxy
for how ill a patient is. The stratifying variables are chosen to demonstrate the method and to allow a comparison with
the DOAC Scotland study results. The identification of potential confounders is not part of this analysis. As in the original
study, Rivaroxaban was chosen to be the baseline treatment. The distributions of the treatment exposures across the
clusters is shown in Figure 1.We can see similar patterns of time under treatment in each cluster but with larger exposure
times across all treatments in the older groups with 5+ concomitant medications. We may expect that rare outcomes
will show up more in the groups who have been under treatment for the longest times. Figure 2 shows the summary
data and 90% posterior intervals for the increase or decrease in outcome rate of Apixaban and Dabigatran compared
with Rivaroxaban for the single-cluster analysis. Outcomes which exceed the 90% posterior probability of an increase
or decrease in rate compared with the baseline (Rivaroxaban) are an increase in Myocardial infarction for Apixaban, a
decrease inOther bleed for bothApixaban andDabigatran, and a decrease inPulmonary embolism forDabigatran (Table 7).
The aggregation of the overall study population into a single cluster may hide differences in treatment behavior, which
are cluster specific. Of interest is investigating if the outcomes flagged in Table 7 in the single cluster analysis are flagged
in each of the individual clusters as defined in Table 6 and if there are any additional outcomes which are not flagged
in the single cluster analysis, but which have a high posterior probability of an increase or decrease in rate in any of the
clusters in the multicluster model.
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TABLE 6 Cluster characteristics Cluster name Sex Age Concomitant Medications Size
M/0-64/0-4 M 0-64 0-4 634
M/0-64/5+ M 0-64 5+ 1382
M/65+/0-4 M 65+ 0-4 673
M/65+/5+ M 65+ 5+ 5367
F/0-64/0-4 F 0-64 0-4 133
F/0-64/5+ F 0-64 5+ 596
F/65+/0-4 F 65+ 0-4 455
F/65+/5+ F 65+ 5+ 5548
F IGURE 1 Total time under
treatment in days for each cluster
M/0−64/0−4 M/0−64/5+ M/65+/0−4 M/65+/5+ F/0−64/0−4 F/0−64/5+ F/65+/0−4 F/65+/5+
Total time under treatment by cluster
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ea
tm
en
t
0
20
00
00
40
00
00
60
00
00
80
00
00
10
00
00
0
Rivaroxaban
Apixaban
Dabigatran
When the models were fitted to the multicluster data 10 combinations of outcome, treatment, and cluster were
flagged as exceeding the 90% posterior probability of an increase or decrease in rate compared with the baseline. The
single cluster results flagged in Table 7 accounted for seven of these. These outcomes generally had high posterior prob-
abilities in many of the clusters but not always above the 90% threshold and in some clusters there was no evidence
of a difference. Taking Myocardial infarction as an example, there was little or no evidence in clusters M/0-64/0-4,
M/65+/0-4, and F/0-64/0-4 of an increase in rate compared with Rivaroxaban (Figure 3). However clusters M/0-64/0-4,
M/65+/0-4, and F/0-64/0-4 are approximately nine times smaller than the largest clusters (M/65+/5+ and F/65+/5+),
with lower overall exposure times and with correspondingly fewer events. The remaining three combinations for the
outcomes Pulmonary embolism, Other ADR, and Ischemic stroke were flagged only in certain clusters (Table 8). Here
there is some evidence of a decrease in Pulmonary embolism and Other ADR for females over the age of 65 years with
five or more concomitant medicines when using Apixaban compared with Rivaroxaban, and also a decrease in Ischemic
stroke for males aged under 65 years with five or more concomitant medications when using Dabigatran compared with
Rivaroxaban. However, the posterior probabilities in the other clusters indicate no appreciable differences between the
treatments.
4.2.1 Discussion
The Bayesian model suggests that compared with Rivaroxaban, there is an increase inMyocardial infarction when being
treated by Apixaban, and that there are lower rates of Other bleed for both Apixaban and Dabigatran and lower rates of
Pulmonary embolism for Dabigatran. There are also indications of possible decreases of Pulmonary embolism and Other
ADR for Apixaban and Ischemic stroke for Dabigatran, compared with Rivaroxaban for some groups.
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All outcomes
Treatment
Apixaban
Apixaban
Apixaban
Apixaban
Dabigatran
Apixaban
Dabigatran
Apixaban
Dabigatran
Apixaban
Dabigatran
Dabigatran
Dabigatran
Dabigatran
Apixaban
Dabigatran
Apixaban
Dabigatran
Grouping
I00−I99
I00−I99
I00−I99
I00−I99
G00−G99
G00−G99
I00−I99
I00−I99
OTHER_ADR
BLEED
I00−I99
I00−I99
BLEED
I00−I99
OTHER_ADR
I00−I99
BLEED
BLEED
Outcome
Myocardial infarction
Haemorrhagic stroke
Systemic embolism
Ischemic stroke
Transient ischaemic attack
Transient ischaemic attack
Myocardial infarction
Pulmonary embolism
Other ADR
Gastrointestinal bleed
Systemic embolism
Ischemic stroke
Gastrointestinal bleed
Haemorrhagic stroke
Other ADR
Pulmonary embolism
Other bleed
Other bleed
P(θ < 0)
0.000
0.020
0.060
0.045
0.058
0.077
0.100
0.447
0.305
0.302
0.455
0.115
0.304
0.606
0.794
0.957
0.943
1.000
P(θ = 0)
0.000
0.420
0.501
0.777
0.833
0.823
0.859
0.517
0.663
0.667
0.516
0.858
0.672
0.384
0.200
0.042
0.056
0.000
P(θ > 0)
1.000
0.560
0.439
0.178
0.109
0.100
0.041
0.035
0.032
0.031
0.030
0.027
0.024
0.010
0.006
0.001
0.000
0.000
−2.5 −2 −1.5 −1 −0.5 0 0.5 1
θ: Median and 90% HPI
F IGURE 2 Posterior summaries of the increase/decrease in rate (𝜃) for all outcomes compared with baseline treatment Rivaroxaban.
All posterior probabilities rounded to three decimal places
While the original study looked at modeling single outcomes up to occurrence or a censoring point,2 the analysis in
this section took into account all outcomes of interest occurring under treatment, including treatment switches. Even
with this difference in approach the results in this section are widely in agreement with those reported in the original
study.2 Both analyses identified that the risk ofMyocardial infarctionwas higher among Apixaban patients in comparison
with Rivaroxaban and Dabigatran, and the risk of Other bleeds was higher among Rivaroxaban patients than Apixaban
and Dabigatran. For Pulmonary embolism, the point-mass model did indicate the possibility of a decrease in rate for
Apixaban but this was only flagged in the cluster F/65+/5+, for the nonclustered model we can see that overall there is
some indication of reduced rates for Apixaban (Figure 2). Pulmonary embolism is however flagged as having a reduced
rate for Dabigatran. For Gastrointestinal bleed, which had an increased risk for Rivaroxaban compared with Apixaban
and Dabigatran in the original analysis, there were also indications of increased rate in the Bayesian analysis but none
that were flagged at the 90% posterior probability level in any of the clusters. We can see this in Figure 4.
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TABLE 7 Outcomes with
increased/decreased rate compared
with Rivaroxaban (greater than 90%
posterior probability)
Outcome Grouping Treatment Increase/decrease
Myocardial infarction Circulatory system Apixaban Increase
Other bleed Bleeds Apixaban Decrease
Other bleed Bleeds Dabigatran Decrease
Pulmonary embolism Circulatory system Dabigatran Decrease
Myocardial infarction (Apixaban)
Cluster
M/0−64/5+
F/65+/5+
M/65+/5+
F/0−64/5+
F/65+/0−4
F/0−64/0−4
M/0−64/0−4
M/65+/0−4
P(θ <0)
0.000
0.000
0.000
0.003
0.075
0.407
0.460
0.680
P(θ =0)
0.000
0.000
0.001
0.028
0.256
0.320
0.305
0.237
P(θ >0)
1.000
1.000
0.999
0.969
0.669
0.273
0.235
0.083
−2.5 −2 −1.5 −1 −0.5 0 0.5 1 1.5 2 2.5 3
θ: Median and 90% HPI
F IGURE 3 Posterior summaries of the increase/decrease inMyocardial infarction rates for Apixaban compared with baseline
treatment Rivaroxaban). All posterior probabilities rounded to three decimal places
TABLE 8 Other outcomes with
decreased rates compared with
Rivaroxaban by cluster
Outcome Grouping Treatment Cluster
Pulmonary embolism Circulatory system Apixaban F/65+/5+
Other ADR Adverse Drug Reactions Apixaban F/65+/5+
Ischemic stroke Circulatory system Dabigatran M/0-64/5+
Including concomitant medications as a stratifying variable poses a number of interesting questions. While it may
be considered a proxy for how ill a patient is, including only counts of medications leaves out the additional infor-
mation regarding what the medications are and how they may affect the overall balance of the clusters. The actual
effect of the medicines is unquantifiable in this analysis. Referring to Figure 3 where a number of clusters have no
indication of an increase in Myocardial infarction, we know from Figure 1 that some of these clusters have lower
overall exposure times. A question here is whether the differences between different clusters is due to the low event
rates and exposure times or due to some other reason, for example, the unknown effect of the concomitant medica-
tions. A clustering approach taking into account the types of medicines that patients were prescribed rather than just
the counts may be a better way of stratifying the data. In the general case, as data accumulates over time, it should
be possible to see the emerging patterns of events more clearly. While confounding cannot be ruled out and it can-
not be guaranteed that the clusters are well balanced, this particular analysis was designed to be comparable with
the original Scotland DOAC study.2 The ability to plot and assess the outcomes using posterior probabilities allows
an assessment to be made of differences between different clusters and which of these differences are worthy of fur-
ther investigation. In general, the inclusion of clusters into the model does allow for an analysis of broadly similar
groups, limited only by the number of patients in the study, the numbers of outcomes, and the information that is
available.
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Gastrointestinal bleed (Apixaban/Dabigatran)
Trt.Grp
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Apixaban
Dabigatran
Dabigatran
Dabigatran
Dabigatran
Dabigatran
Dabigatran
Dabigatran
Dabigatran
Cluster
M/65+/5+
M/65+/0−4
M/0−64/5+
M/0−64/0−4
F/65+/5+
F/65+/0−4
F/0−64/5+
F/0−64/0−4
M/65+/5+
M/65+/0−4
M/0−64/5+
M/0−64/0−4
F/65+/5+
F/65+/0−4
F/0−64/5+
F/0−64/0−4
P(θ <0)
0.250
0.794
0.113
0.520
0.167
0.740
0.511
0.552
0.150
0.722
0.399
0.282
0.264
0.553
0.692
0.552
P(θ =0)
0.714
0.187
0.633
0.421
0.780
0.241
0.439
0.385
0.779
0.254
0.541
0.612
0.695
0.411
0.281
0.397
P(θ >0)
0.035
0.018
0.254
0.059
0.053
0.019
0.049
0.064
0.071
0.023
0.060
0.105
0.041
0.036
0.027
0.051
−2 −1.5 −1 −0.5 0 0.5
θ: Median and 90% HPI
F IGURE 4 Posterior summaries of the increase/decrease in Gastrointestinal bleed infarction rates for Apixaban compared with
baseline treatment Rivaroxaban). All posterior probabilities rounded to three decimal places
5 DISCUSSION
The availability of large scale databases containing the health records of thousands of patients, each record containing
multiple variables, provides an opportunity and a requirement to move beyond a single variable analysis and develop
methods capable of analyzing multiple outcomes, providing the possibility of moving toward a more precise approach to
medicine delivery. In order to harness the data, a number of challengesmust bemet. Balance between comparator groups
is not guaranteed in observational data, and the application of propensity scoring methods for a fully causal analysis
may not be possible. Multivariate methods require the assumption that relationships exist between different outcomes,
and the outcomes themselves may be rare. Hierarchical relationships among outcomes, such as those defined by medical
dictionaries and used in clinical trials, are particularly useful and suitable for statistical modeling. However, a similar
well-defined structure does not exist for the type of clinical data routinely recorded for patients in the general population.
The lack of balance between comparator groups may be addressed by matching,6 and the possibility of the existence of
genetic markers as a potential method for stratifying groups has the ability to address this issue more fully.7
Hierarchical Bayesianmethods are a suitable approach for analyzing this type of data. Hierarchies of outcomesmay be
easily incorporated in models, and posterior probabilities provide a method for assessing outcome occurrence. Bayesian
methods are also well suited to handling the analysis of constantly accumulating data, such as healthcare records. These
methods are well understood and have the advantage of being relatively easy to explain to clinicians. The methods out-
lined in this article take a summary approach to data modeling where patients' times under treatment are combined
within different clusters to provide an analysis of the differences between different treatments within these clusters. The
inclusion of the point-mass term has the effect of requiring a strong signal in order for an outcome to be a candidate for
being associated with a treatment. The model is flexible with regard to choice of clusters and hierarchies. The longitu-
dinal analysis of outcomes may be affected by a number of factors. It is not possible to guarantee patient adherence and
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there may also be gaps in the prescription record (data quality). It is also not easily possible to determine different periods
of drug action that would successfully cover all treatments. For some treatments, short discontinuations may be impor-
tant. This is the case for drugs such as direct oral anticoagulants where the half-life may be less than a day.12 For other
treatments, where the risk of cumulative damage from the treatment is large, the patient may continue to be at risk after
discontinuation, and the outcome rate itself may be variable.
The use of machine learning techniques to address complex healthcare problems is growing25 and in particular, the
use of hierarchical models and modeling of relationships between outcomes is becoming more common in healthcare
data analysis.9,13,16 Modeling outcomes simultaneously provides a number of advantages over single variable analyses
including multiple comparison control, the borrowing of strength between effects, and the shrinkage of nonsignificant
effects toward zero. However beyond the modeling of outcomes real clinical decisions need to made. The stratification of
a population into a set of balanced clusters, and the inclusion of this in themodel, brings forward the possibility ofmaking
clinical decisions based on treatment comparisons within these clusters. However, the model alone is unable to provide
this and would require an associated decision-making procedure. Looking beyond the models presented here, which
assumes that patients are stratified and that groupings are fixed, there is the possibility of moving to a more integrated
Bayesian approach to this type of healthcare analysis, with the possibility of the inclusion in the model of treatment
relationships and uncertainty regarding cluster membership, outcome groupings, and treatment allocation,26 allowing
an extendable probabilistic framework.
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APPENDIX A. MODEL DEFINITIONS
There are C treatments,H strata, B groupings of outcomes with kb outcomes in group b, and the number of outcomes
for the jth outcome in the bth group for treatment c in stratum h is X (c)bj,h. The model is:
X (c)bj,h ∼ Poisson
(
𝜆
(c)
bj,hT
(c)
bj,h
)
T(c)bj,h =
∑
i∈(c)bj,h
tih
log 𝜆(c)bj,h = 𝛾bj,h + x(c)𝜃
(c)
bj,h
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F I GURE A1 Directed acyclic
graph for the model
h = 1,… ,H, b = 1,…Bh, j = 1,… kbh
c = 1,… ,C; x(c) = 1; x(i) = 0, i ≠ c. (A1)
The priors for the model parameters and hyperparameters are given in Equations (A2)-(A4). As this is a three-level
hierarchical model we have three levels of priors:
𝛾bj,h ∼ N(𝜇𝛾b, 𝜎2𝛾b) 𝜃
(c)
bj,h ∼ 𝜋
(c)
b I[𝜃(c)bj,h=0] + (1 − 𝜋
(c)
b )N(𝜇
(c)
𝜃b , (𝜎
(c)
𝜃b )
2) (A2)
𝜇𝛾b ∼ N(𝜇𝛾0, 𝜏2𝛾0) 𝜇
(c)
𝜃b ∼ N(𝜇
(c)
𝜃0 , (𝜏
(c)
𝜃0 )
2)
𝜎2
𝛾b ∼ IG(𝛼𝛾 , 𝛽𝛾 )
(
𝜎
(c)
𝜃b
)2
∼ IG(𝛼𝜃, 𝛽𝜃)
𝜋
(c)
b ∼ Beta(𝛼
(c)
𝜋 , 𝛽
(c)
𝜋 ) (A2)
𝜇𝛾0 ∼ N(𝜇𝛾00, 𝜏2𝛾00) 𝜇
(c)
𝜃0 ∼ N(𝜇𝜃00, 𝜏
2
𝜃00)
𝜏2
𝛾0 ∼ IG(𝛼𝛾00, 𝛽𝛾00)
(
𝜏
(c)
𝜃0
)2
∼ IG(𝛼𝜃00, 𝛽𝜃00)
𝛼
(c)
𝜋 ∼ M(𝜆𝛼)I(𝛼(c)𝜋 > 1) 𝛽(c)𝜋 ∼ M(𝜆𝛽)I(𝛽(c)𝜋 > 1), (A4)
where I(.) is the indicator function, N is the normal distribution, 𝛽 is the beta distribution, IG is the inverse-gamma
distribution, and M is the exponential distribution.
The following model hyperparameters all have common values over the intervals based on the values in Berry and
Berry:9
𝜇𝛾00 = 0, 𝜏2𝛾00 = 10, 𝛼𝛾 = 3, 𝛽𝛾 = 1, 𝛼𝛾00 = 3, 𝛽𝛾00 = 1, 𝜆𝛼 = 1
𝜇𝜃00 = 0, 𝜏2𝜃00 = 10, 𝛼𝜃 = 3, 𝛽𝜃 = 1, 𝛼𝜃00 = 3, 𝛽𝜃00 = 1, 𝜆𝛽 = 1. (A5)
Assuming conditional independence of the parameters themodels are fitted usingMarkov chainMonte Carlo (Gibbs)
sampling. The graph of the model is shown in Figure A1.27
APPENDIX B . SIMULATION STUDY
The outcomes, their groupings, and the increases in rates for outcomes associated with treatments are presented in
Tables 2 and 3. The general simulation parameters are given in Table B1. For each simulation, the underlying baseline
rates for the outcomes are sampled from a normal distribution with mean 𝜇 and standard deviation 𝜎, with negative rates
set to 𝜇. Patients are randomly assigned to the clusters with the probabilities in Table B2. The average treatment time in
each cluster was generated from a normal distribution with mean 𝜇C and standard deviation 𝜎C. The values used in the
simulation are given in Table B2. The average time a patient in each cluster remains under treatment is generated from
16 CARRAGHER et al.
Parameter Description Value
N Number of treatments 4
C Number of clusters 10
NC Number of outcomes 9
Ng Number of outcome groups 3
Np Number of patients per simulation 14 000
NS Number of simulations 1000
𝜇 Baseline outcome mean rate 0.001
𝜎 Baseline outcome standard deviation 0.0001
𝜇C Cluster mean treatment time 339
𝜎C Cluster treatment time standard deviation 150
𝜎p Patient treatment time standard deviation 10
TABLE B1 General simulation parameters
Cluster Patient assignment probability Mean treatment duration
Clusters1 0.025 557
Clusters2 0.05 444
Clusters3 0.05 275
Clusters4 0.1 499
Clusters5 0.1 533
Clusters6 0.1 460
Clusters7 0.1 312
Clusters8 0.1 167
Clusters9 0.175 540
Clusters10 0.2 287
TABLE B2 Cluster simulation
parameters
Treatment Cluster Patient assignment probability
Drug1 Cluster1-Cluster5 0.2
Drug2 Cluster1-Cluster5 0.2
Drug3 Cluster1-Cluster5 0.2
Drug4 Cluster1-Cluster5 0.4
Drug1 Cluster6-Cluster10 0.25
Drug2 Cluster6-Cluster10 0.25
Drug3 Cluster6-Cluster10 0.25
Drug4 Cluster6-Cluster10 0.25
TABLE B3 Treatment assignment
probabilities
a normal distribution with mean treatment duration given in Table B2 and standard deviation 𝜎p. Patients are randomly
assigned treatments with probabilities given in Table B3. Outcomes are generated for each patient by a Poisson process
with parameter given by the outcome rate multiplied by the treatment duration. The data were summarized by treatment
and cluster for input to the model.
